HERV-K (human endogenous retrovirus type K) type 1-encoded Np9 is a tumor-specific biomarker, but its oncogenic role and targets in human leukemia remain elusive. We first identified Np9 as a potent viral oncogene in human leukemia. Silencing of Np9 inhibited the growth of myeloid and lymphoblastic leukemic cells, whereas expression of Np9 significantly promoted the growth of leukemia cells in vitro and in vivo. Np9 not only activated ERK, AKT and Notch1 pathways but also upregulated b-catenin essential for survival of leukemia stem cells. In human leukemia, Np9 protein level in leukemia patients was substantially higher than that in normal donors (56% vs 4.5%). Moreover, Np9 protein level was correlated with the number of leukemia stem/progenitor cells but not detected in normal CD34
INTRODUCTION
Leukemia is a common hematopoietic tumor of unknown etiology, which is estimated to affect 250 000 people worldwide. Unfortunately, the majority of leukemia patients will die due to drug resistance or relapse. Currently, the uncertain etiology and molecular mechanisms greatly hamper development of efficient drugs and regimens for curing this malignant disease. Retroviruses have been etiologically linked to a number of animal leukemias, and a rare type of human leukemia: human adult T-cell leukemia/ lymphoma, 1,2 but not to human common leukemia, such as acute and chronic myeloid leukemia (AML and CML, respectively), acute (ALL) and chronic lymphoblastic leukemia.
Human endogenous retrovirus sequences (HERVs), which constitute up to 8% of the human genome, [3] [4] [5] reside in the human genome for several million years. Although the majority of HERVs are dysfunctional due to the accumulation of multiple nonsense mutations, some are still active and may have a potential function, notably the HERV type K (HERV-K) family. [6] [7] [8] [9] [10] [11] [12] Reactivation of HERV-K was frequently observed in patients with immunodeficiency. For instance, HERV-K was persistently present in AIDS patients who failed to respond to HAART before and after HIV-1 rebounds but undetectable in patients with successful HAART treatment. 13 These data suggest that HERV-K could be reactivated under condition of immunosuppression, and the immune system, especially T cells targeted by HIV-1, may have a critical role in immune surveillance of HERV-K. Interestingly, reactivation of several members of HERV-K family, such as HERV-K type 1 and 2, was observed in a variety of human tumors, such as leukemia, 14 lymphoma, 15 breast cancer 16, 17 and melanoma. 18 The viral Np9 transcript, a small regulatory gene encoded by HERV-K type 1, has been shown to be exclusively present in tumors and transformed cells. 17 Our previous studies have demonstrated the presence of retrovirus particles in primary leukemia cells from patients with AML. 19 In addition, the viral Tax protein of human T-cell leukemia virus type 1 has been implicated in leukemogenesis. 20 However, Np9 protein expression and its possible role in human common leukemia have not been studied.
The aim of this study was to investigate whether the native Np9 protein is expressed in human leukemia cells and whether the viral Np9 has a role in cell growth of human common leukemia, including myeloid and lymphoblastic leukemia. If so, we then further assess possible molecular mechanism by which Np9 promotes the growth of leukemia cells and correlation between Np9 protein levels and CD34 þ leukemia cells. We show that the native Np9 protein is highly expressed in 56% of leukemia patients but rarely detected in both the normal CD34 þ hematopoietic stem 1 cells and blood cells. Unexpectedly, Np9 could activate b-catenin, extracellular signal-regulated kinase (ERK), Akt and Notch1 signaling pathways and promote the growth of human myeloid and lymphoblastic leukemia cells. Moreover, Np9-positive samples highly express leukemia-specific pol-env polyprotein, env and transmembrane (TM) proteins as well as viral particles. In addition, there is a positive correlation between Np9 protein levels and the number of CD34 þ leukemia cells in primary leukemia samples. Thus, these findings define the Np9 as a potent viral oncogene and reveal a novel mechanism of leukemia stem/progenitor cell growth driven by the viral oncogene Np9 via co-activating multiple oncogenic signaling pathways as a molecular switch.
METHODS

Reagents and antibodies
The viral Np9 and K-env rabbit antibodies were prepared in our lab and the antibody dilutions for western blotting were 1:200 and 1:10 000, respectively. The Np9 antibody was raised against the peptide TAPKRQRPSRTGHD of Np9 protein and the K-env antibody was raised against the peptide SKRKGGNVGKSKRD of HERV-K type 1 env protein. Both Np9 and K-env antibodies were purified using affinity chromatography with above corresponding Np9 and K-env peptides. The Np9 antibody well recognized recombinant Np9 protein (Supplementary Figures S1A-C) and endogenous Np9 proteins (Supplementary Figures S1D-E) using western blot assay. In addition, the specificity of Np9 antibody was further confirmed using endogenous Np9 protein from both primary leukemia cells and leukemia cell lines as well as recombinant Np9 protein by peptide blocking assay (Supplementary Figures S1A-E) . b-catenin, c-myc and Noth1 rabbit antibodies were purchased from Cell Signaling Technology, Danvers, MA, USA. Ras, Grb2, phosphor-Akt, Akt and PLZF (promyelocytic leukemia zinc finger) antibodies were obtained from Santa Cruz Biotechnology, Dallas, TX, USA. ERK1/2 and phosphor-ERK1/2 antibodies were from Bioworld Technology, Louis Park, MN, USA. Numb antibody was from Abcam, Cambridge, UK.
Cell lines and culture
In all, 14 various human hematopoietic malignant cell lines and 16 different solid tumor cell lines were used in this study. Hematopoietic Transmission electron microscopy, viral particle isolation and RNA detection Transmission electron microscopy was performed as routine methods. Extracellular virions were purified from the supernatants of cultured leukemia cells using ultracentrifugation on sucrose gradient. Viral RNA was extracted from virions using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and used for amplification of viral env reading-frame transcripts as previously described. 17 
Subcellular localization assay
For subcellular localization assays, cells were transfected with pEGFP-C1-Np9 plasmid for 48 h. Cell nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole; blue) followed by observation under Zeiss Confocal Laser Scanning Microscope 710. (Carl Zeiss MicroImaging GmbH, Jena, Germany).
Western blot analysis
Cell specimens were washed twice with phosphate-buffered saline (PBS) buffer and total cellular protein was extracted using radio-immunoprecipitation assay. Cell extracts were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (10% polyacrylamide gels) and then transferred to nitrocellulose membranes (Whatman, Kent, UK) and blocked with 5% nonfat milk in PBS-Tween 20(PBS-T) and then reacted with primary antibodies overnight at 4 1C. Np9 acts as a molecular switch for human leukemia T Chen et al
Construction of Np9 shRNA lentivirus
The RNA interference target sequences for NP9 were chosen by the shRNA design software BLOCK-iT RNAi Designer (Invitrogen) and siRNA target finder (Ambion, Austin, TX, USA). The four shRNAs targeted 5
0 and 5 0 -AGAAGTAGACATAGGAGAC-3 0 in the message RNA sequences of NP9. The single-strand DNA oligos were synthesized by Oligo Entry System in the City of Hope Medical Center. The oligos were phosphorylated by T4 PNK (New England Biolabs, Ipswich, MA, USA) and annealed. The annealed shRNA and scramble control oligos were ligated into the lentiviral vector pLKO-puro.1 (Sigma, St Louis, MO, USA), which had been digested by EcoR1 and Age1. The lentivirus was packaged with the helper plasmids expressing gag, pol, VSV-G env and rev2 by co-transfection of Hek293T cells. The supernatant of the Hek293T cells that packages lentivirus targeting NP9 was harvested, titrated and pooled with a ratio 1:1:1:1. Jurkat and K562 cells were transduced with the lentivirus with an MOI (multiplicity of infection) of 10 for two or three times and selected by puromycin (Clontech, Mountain View, CA, USA).
Construction of Np9 and Rec lentivirus vectors and tumor xenograft
To generate Raji stable cell lines that express Np9 or Rec, the proteincoding sequence was cloned into a lentiviral vector with MSCV promoter (5 0 untranslated region) and puromycin resistance gene. The vectors were then used to package lentivirus and infect the Raji cells with an MOI of 3. The Raji cells were then selected with puromycin for 1 week and used for xenograft. In all, 5 Â 10 6 cells were suspended in PBS containing 30% growth-factor-reduced Matrigel and applied for subcutaneous injection for one mouse in a volume of 200 ml. To analyze Np9 and Rec overexpression in stable cells and xenografted tumors, quantitative real-time PCR was performed with the following primers: Np9-forward, ccatcggagatgcaa agaaaa; Np9-reverse, ccatcggagatgcaaagaaaa; Rec-forward, gagcaccgttgac tcacaagat; and Rec-reverse, ctgcaagcagcatactctctgg. Western bloting was used to detect Np9 protein.
Colony-formation assay
In all, 400 cells were cultured in a 96-well plate using IMDM medium with 15% fetal calf serum at 37 1C in a 95% air, 5% CO 2 humidified incubator for 14 days. Three wells of cell colonies were scored (X40 cells).
Statistical analysis
Results are expressed as means ± s.e.m. Differences were evaluated by t-test analysis of variance. Two-Sample Kolmogorov-Smirnov test was used to evaluate correlation between Np9 protein and CD34 þ leukemia cells in primary leukemia samples. P-values o0.05 were considered statistically significant. Figures 1a and b) . To assess whether Np9 promotes the growth of leukemia cells, we generated recombinant lentiviruses expressing Np9 and transduced to Np9-negative human leukemia Raji cells and determined growth curves of Raji cells with overexpression of Np9 and found that Np9 significantly promoted the growth of Raji cells (Figure 1c , *Po0.01). We next examined the effects of Np9 expression on the colony-forming ability of tumor cells using colony-forming assay. In contrast to control, Np9 overexpression induced an increase in the number of colonies (Figure 1d , *Po0.01). More importantly, the size of the colonies induced by Np9 overexpression was larger than that of control ( Figure 1e ). These data suggest that Np9 is essential for maintaining and promoting the growth of leukemia cells. In addition, we also evaluated the subcellular localization of the Np9 protein and found that viral Np9 protein was predominantly localized in the nucleus of leukemia cells, but a small amount of viral Np9 protein was also observed in the cytoplasm of tumor cells (Figure 1f ). To confirm whether Np9 promotes the growth of leukemia cells in vivo, Raji cells with Np9 overexpression or control cells were injected subcutaneously into immunocompromized NOD-SCID (nonobese diabetic/severe combined immunodeficient) mice following standard protocols. The viral Rec gene, which has been shown to be oncogenic, 21 was used as positive control. Consistent with above observations, we observed that tumors in mice (n ¼ 6) that received cells with Np9 grew much faster (Figures 2a and c) , and tumor weight was 1.74 ± 0.42 g within 25 days (Figures 2d-f ; Po0.01). By contrast, tumors in mice that received empty vector as negative control grew slowly (Figures 2a  and c) and tumor weight was 0.62±0.18 g within 25 days (Figures  2d-f) . The tumor weights with Np9 expression were increased by 2.81 times. Western blot analysis results indicate that Np9 protein specifically expressed in corresponding xenografts and cell lines (Figure 2g ). These data clearly indicate that Np9 expression strongly supports and promotes the growth of leukemia cells in NOD-SCID mice.
Np9 activates b-catenin, ERK, Akt and Notch1 signaling molecules As co-activation of multiple cancer-related signaling pathways conferring resistance to single anti-cancer agent has been demonstrated in several solid tumors such as brain tumor glioblastoma, 22 we next examined whether Np9 expression co-activates Wnt/b-catenin, Notch1, ras/ERK and c-myc/AKT signaling pathways, which are aberrantly activated in human leukemia, [23] [24] [25] [26] [27] [28] [29] [30] [31] in four different leukemia cell lines (K562, Kasumi-1, NB4 and Jurkat) with high levels of Np9 expression (Figure 3) . The results showed that these leukemia cell lines had a co-activation of multiple leukemia-associated signaling pathways (Figure 3 ). For instance, K562 cells showed a co-activation of Notch1 (Figure 3a) , ERK (Figure 3b ), c-myc/Akt (Figure 3c ) and b-catenin (Figure 3d ), whereas Jurkat cell line displayed a co-activation of Notch1 (Figure 3a) , c-myc/Akt (Figure 3c ) and b-catenin (Figure 3d) . In contrast to leukemia cells, no obvious activation of these leukemia-related signaling pathways was observed in normal blood cells from healthy donors (Figure 3e ). To address whether Np9 affects these signaling components, we transfected 
Np9-negative Raji cells using Np9 expression plasmid and observed that overexpression of Np9 led to a marked upregulation of b-catenin, phospho-ERK (pERK), c-myc and cleaved Notch1 with a concomitant decrease of Numb (Figure 4a ). To validate these results, we then silenced Np9 gene expression in K562 and Jurkat leukemia cells using shRNAs. The results revealed that Np9 silencing caused significant decreases of expression levels of c-myc, pERK1, phospho-Akt (pAkt) and cleaved Notch1 with a concomitant increase of Numb (Figures 4b and c) . Table S1 ). Significantly, of the 50 primary leukemia samples, 28 (56%) showed expression of Np9 protein. By contrast, Np9 protein was rarely detected in 1 of 22 (4.5%) normal hematopoietic cells from healthy individuals (Table 1) . These results indicate that Np9 protein expression is universal in both human leukemia cell lines and primary leukemia samples but rarely in normal blood cells. We further analyzed correlations between the viral Np9 protein, b-catenin, cleaved Notch1, ERK and c-myc levels in primary leukemia samples. The chronic myelomonocytic leukemia sample was used as a Np9-negative control. Consistent with the above observations, Np9 protein levels were positively associated with co-activation of b-catenin, cleaved Notch1, pERK1/2 and c-myc in primary leukemia specimens (Figure 5b and Supplementary Table S2 ). 
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Np9-positive samples highly express leukemia-specific pol-env polyprotein, env and TM proteins Based on whether an 292 bp at the pol-env boundary are present or deleted, HERV-K genomes can be classified as type 1 or type 2.
HERV-K type 1 (HERV-K-1) can produce a pol-env polyprotein caused by a frameshift that fused Env in frame to the carboxyl portion of Pol due to the 292 bp deletion. 17 As Np9 gene is within the HERV-K env-reading frame and transcribed exclusively from HERV-K type 1 provirus, we next asked whether Np9-positive leukemia samples also express pol-env polyprotein, env and TM proteins using a specific antibody against a defined domain of Env, the TM domain. As expected, both leukemia cell lines and primary leukemia samples also expressed leukemia-specific pol-env polyprotein (B160 kDa), env protein (B70 kDa) and TM proteins (B30 kDa, B35 kDa) (Figures 6a and b) . By contrast, these leukemia-specific viral proteins were not detected in normal blood cells from 12 normal individuals (Figure 6c) . Intriguingly, these viral proteins, particularly the TM proteins, decreased or even disappeared in leukemia patients with complete remission after combination chemotherapy (Figure 6d ). In addition, transmission electron microscopy showed that retroviral particles were frequently observed in both the primary myeloid and lymphoblastic leukemia cells after treatment with a cocktail of retrovirus inducers for 7 days (Figures 7a and b) . Moreover, virus particles in leukemia cells released into cell culture supernatants (Figure 7c (Figure 4a ), a critical regulator of survival and proliferation of CD34 þ leukemia stem cells, 23, 24 we next examined the Np9 protein levels in CD34 þ leukemia stem/progenitor cells in primary leukemia samples. Out of 28 Np9-positive primary leukemia samples, 21 exhibited strong expression of Np9 protein, including AML, ALL and CML. Significantly, Np9 expression could not be detected in CD34 þ hematopoietic stem cell sample from healthy individual which indicated that Np9 protein levels were positively correlated with CD34 þ leukemia stem/progenitor cells (P ¼ 0.003; Supplementary Figure S2 ; Table 1 ). Consistently, Np9 protein levels were also significantly associated with b-catenin protein in primary leukemia cell samples (Figure 5b ). These observations indicate that the viral Np9 protein may be essential for the survival and proliferation of leukemia stem/progenitor cells. Figure S3A) . Alignment analysis showed that amino-acid sequences deduced from five ORFs for Np9 were highly similar (Supplementary Figure S3A) , suggesting that Np9 proteins are highly conserved in the human genome. Notably, we identified a Grb2 SH3 (N)-typical motif (PxxPxR) among these deduced Np9 proteins (Supplementary Figure S3B) . This motif was absolutely conserved throughout all Np9 proteins (Supplementary Figure S3B) , indicating a potential role in Np9-mediated leukemogenesis. Consistent with this hypothesis, our results have shown that Np9 expression is essential for maintaining ERK1/2 signaling pathway in leukemia cells (Figures 4a and c) . 
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, blast crisis; BM, bone marrow; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CP, chronic phase; CR, complete remission; HSC, hematopoietic stem cell; MDS, myelodysplastic syndromes; ND, not detected. Note: Np9 expression level: strong: þ þ þ ; moderate: þ þ ; weak: þ ; negative: À . 50 primary leukemia samples, þ þ þ : 42.0% (21/50); þ : 56.0% (27/50 
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DISCUSSION
The HERV-K type 1-encoded Np9 is a tumor-specific biomarker, but its oncogenic role and targets in human leukemia are largely unknown. Our present study defines the Np9 as a novel potent viral oncogene and a critical molecular switch of multiple signaling pathways regulating the growth of human myeloid and lymphoblastic leukemia cells. Indeed, we observed that relatively high amounts of the native Np9 protein were invariably present in the majority of myeloid and lymphoblastic leukemia cell lines and primary leukemia patient samples but not in normal blood cell samples. Importantly, Np9 protein expression is essential for survival and growth of both myeloid and lymphoblastic leukemia stem/progenitor cells. Surprisingly, we also found that Np9 could activate multiple leukemia stem/progenitor cell-related signaling pathways such as Wnt/b-catenin, c-myc/AKT, ras-ERK and Notch1 signaling pathways, which can partially account for diversity and heterogeneity of human common leukemia and help to explain why leukemia is so difficult to cure using current agents targeting single signaling pathway. These findings raise the possibility that targeting the viral Np9 gene may effectively kill leukemia stem/ progenitor cells and have more significant clinical efficacy in human common leukemia. A striking result of the present work is that native Np9 protein was detected in 78.57% of various leukemia cell lines (11/14) and 56% of primary leukemia cell samples (28/50). Moreover, Np9 protein level in leukemia patients is substantially higher than that in normal donors (56% vs 4.5%). It has been reported that HERV-K type 1 and 2 is frequently reactivated in a variety of human tumors, such as leukemia, 14 lymphoma, 15 breast cancer 16, 17 and melanoma. 18 The viral gene Np9 is a regulatory gene encoded by HERV-K 1, and its transcript is exclusively present in tumors and transformed cells, 17 but the native Np9 protein was not reported in both leukemia cell lines and primary leukemia samples to date. Besides expressing native Np9 protein in leukemia cells, we also found that Np9-positive samples frequently expressed leukemiaspecific pol-env polyprotein, env and TM proteins as well as viral particles. Furthermore, these viral protein levels, particularly the TM proteins, were positively correlated with disease status. These results indicate that primary leukemia cells harbor a replicationcompetent homolog of HERV-K type 1 genome. The exclusive presence of the viral Np9 protein, pol-env polyprotein, envelope and TM proteins in primary leukemia cells, together with inverse correlation between these viral proteins and disease status, strongly suggests that an unidentified homolog of HERV-K type 1 may exist in human leukemia cells. The role of viral particles in leukemia cells is uncertain to date. Human T-cell leukemia virus type 1 retrovirus has been well linked to etiology of adult T-cell leukemia/lymphoma, and the viral particles is rarely observed in fresh primary leukemia cells but easily detected in cultured leukemia cells after induced by IdUR.
The viral Tax protein, a well-known regulatory protein encoded by human T-cell leukemia virus type 1 has been implicated in leukemogenesis. 20 Moreover, the viral gene Rec (also called cORF), a regulatory gene encoded by HERV-K type 2 (HERV-K 2), has been shown to support cell transformation and tumor growth in nude mice. 21 To address whether Np9 has a role in human leukemogenesis, we determined the effect of Np9 expression on the growth of human leukemia cells and found that silencing of Np9 significantly inhibited the growth of myeloid and lymphoblastic leukemic cells, whereas expression of Np9 strongly promoted the growth of leukemia cells in NOD-SCID mice. These data indicate that Np9 is essential for survival and growth of myeloid and lymphoblastic leukemia cells.
A further question of interest is how the viral Np9 affects survival and growth of leukemia cells. Unexpectedly, we observed that Np9 expression could upregulate b-catenin, phospho-ERK (pERK), c-myc and cleaved Notch1 with a concomitant decrease of Numb. To further confirm these observations, we assessed the levels of components in Wnt/b-catenin, Notch1, ras/ERK and c-myc/AKT signaling pathways, which are aberrantly activated in human leukemia. [23] [24] [25] [26] [27] [28] [29] [30] [31] Consistently, we also observed a positive correlation of Np9 expression with these cancer-related signaling pathways in both human leukemia cell lines and primary leukemia cell samples. Of note, Np9 protein level was correlated with the Np9 acts as a molecular switch for human leukemia T Chen et al number of leukemia stem/progenitor cells, which is consistent with the fact that Np9 can activate b-catenin, a critical regulator of survival and proliferation of CD34 þ leukemia stem cells. 32 Notch signaling regulates cell specification and homeostasis of stem cell compartments, and it is counteracted by the cell fate determinant: Numb. Both Numb and Notch have been implicated in both human T-cell leukemia 25 and CML blast crisis. 26 However, it is unknown what factor causes aberrant Notch1 signaling. In this study, we demonstrated that Np9 could potently upregulate Notch1 of both myeloid and lymphoblastic leukemia cells by reducing numb protein levels (Figures 4a-c) . As Notch1 signaling is counteracted by the cell fate determinant Numb, 26 and Np9 protein interacts with the RING-type E3 ubiquitin ligase LNX (ligand of Numb protein X), 33 which targets Numb for ubiquitindependent degradation, 34 we propose that the viral Np9 protein may activate Notch1 signaling by targeting Numb for ubiquitinmediated degradation in human leukemia cells. Aberrant activation of c-myc/Akt pathway is a critical pathogenetic event frequently observed in both lymphoblastic and myeloid leukemias, 30, 31 making it an attractive target for therapeutic inhibition. 30, 31 Np9 physically and functionally interacts with the PLZF tumor suppressor, a transcriptional repressor and chromatin remodeler implicated in cancer and the self-renewal of spermatogonial stem cells. 35 Moreover, one major target of PLZF is the c-myc proto-oncogene. 35 Consistent with these data, our results also show that Np9 upregulates c-myc and pAKT. These observations indicate that the viral Np9 could simultaneously or sequentially activate multiple leukemia-related signaling networks essential for the survival and proliferation of both myeloid and lymphoblastic leukemia stem/progenitor cells.
Finally, we identified a Grb2 SH3 (N)-typical motif (PxxPxR) among Np9 proteins. This motif is highly conserved throughout all Np9 proteins (Supplementary Figure S2) , indicating a potential role in Np9-mediated leukemogenesis. Consistent with this observation, our results have shown that Np9 expression is essential for maintaining ERK1/2 signaling pathway in leukemia cells (Figures 4a and c) .
It is clear from our data that the viral Np9 is a critical switch that activates multiple leukemia-related signaling pathways. These findings may have great clinical relevance, because co-activation Np9 acts as a molecular switch for human leukemia T Chen et al of multiple cancer-related signaling pathways confers resistance to single anti-cancer agent in several solid tumors, such as brain tumor glioblastoma. 22 The discovery of Np9 as a potent viral oncogene that co-activates Wnt/b-catenin, Notch1, ERK and Akt signaling pathways essential for the survival and proliferation of leukemia stem/progenitor cells provides a potential novel therapeutic target and opens new perspectives to unravel the etiology of human leukemia.
